160
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Cancer Pharmacogenomics: DNA Genotyping and Gene Expression Profiling to Identify Molecular Determinants of Chemosensitivity

&
Pages 303-315 | Published online: 09 Oct 2008
 

Abstract

Cancer patients exhibit a wide heterogeneity in their responses to chemotherapy. Improvement in chemotherapeutic responses could be achieved by gaining more detailed information on the molecular determinants (i.e., DNA, RNA or protein) underlying this heterogeneity. Pharmacogenomics approaches can be used to integrate information on drug responsiveness with alterations in molecular entities, often on a genome-wide scale. By using information gleaned from pharmacogenomics studies, it is anticipated that cancer chemotherapy can be tailored to the individual patient or tumor phenotype. This review focuses on pharmacogenomics studies conducted to gain insight into the molecular determinants of chemosensitivity to cancer chemotherapeutics.

ABBREVIATIONS
ABCB1/MDR1:=

ATP-binding cassette, sub-family B, member 1/ multidrug resistance 1

ALL:=

acute lymphoblastic leukemia

ASNS:=

asparagine synthetase

CEPH:=

Centre d'Etude du Polymorphisme Humain

CYP2D6:=

cytochrome P450, family 2, subfamily D, polypeptide 6

DNA:=

deoxyribonucleic acid

DPYD:=

dihydropyrimidine dehydrogenase

EGFR:=

epidermal growth factor receptor

ERBB2:=

v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glio blastoma derived oncogene homolog

FDA:=

Food and Drug Administration

5-FU:=

5-fluorouracil

GSTM1:=

glutathione S-transferase M1

mRNA:=

messenger ribonucleic acid

MTHFR:=

5,10-methylenetetrahydrofolate reductase

NCI:=

National Cancer Institute

NSCLC:=

non-small cell lung cancer

RNA:=

ribonucleic acid

RT-PCR:=

reverse transcriptase – polymerase chain reaction

SNPs:=

single nucleotide polymorphisms

TAILORx:=

Trial Assigning Individualized Options for Treatment

TYMS:=

thymidylate synthetase

Acknowledgments

The authors are supported in part by NIH grants U01 GM63340, P50 CA106991, and P30 CA016086.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.